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Abstract: Primary central nervous system vasculitis (PCNSV) is a
rare and poorly understood syndrome. We describe the clinical
findings in 8 patients who appear to have a distinct subset of
PCNSV. We identified 101 consecutive patients with PCNSV who
were seen between January 1, 1983, and December 31, 2003. The
diagnosis was based on conventional angiography in 70 patients
and on central nervous system biopsy in 31 patients. Six of the 31
patients also had angiograms showing changes of vasculitis. Thus,
76 patients of the cohort had abnormal angiograms. Eight of the
101 patients had normal angiograms (Bangiography-negative[) but
had brain biopsies that showed vasculitis. We compared the clinical
and laboratory findings and outcomes of the 8 patients with
angiography-negative PCNSV with those of the 76 patients with
PCNSV whose angiograms showed evidence of vasculitis
(Bangiography-positive[). In comparison with the 76 patients with
angiography-positive PCNSV, the 8 patients with angiography-
negative PCNSV more commonly had 1) a cognitive disorder
(87.5% vs. 43.4%; p = .024); 2) cerebrospinal fluid abnormalities (a
protein level Q700 mg/L or a white blood cell count Q10  106/L)
(100% vs. 35.5%; p = .034); and 3) meningeal or parenchymal
enhancing lesions on magnetic resonance imaging (75.0% vs.
23.9%; p = .007). Other differences between the 2 groups were
observed but were not significantly different. All patients with
angiography-negative PCNSV responded to treatment and none
died. Angiography-negative PCNSV appears to be a distinct sub-
type of cerebral vasculitis with small vessel involvement beyond
the resolution of conventional angiography and is associated with a
favorable outcome.
(Medicine 2008;87:264Y271)
Abbreviations: CNS = central nervous system, CSF = cerebrospinal
fluid, MRI = magnetic resonance imaging, PCNSV = primary central
nervous system vasculitis.
INTRODUCTION
Primary central nervous system vasculitis (PCNSV) is anuncommon condition in which vascular inflammatory
lesions are limited to the brain and spinal cord2,4,13,17. Brain
biopsy provides a definitive diagnosis when results are
positive, but obtaining the sample is an invasive process.
Therefore, the diagnosis of PCNSV is often based on a
cerebral angiogram that shows findings typical of vasculitis,
even though angiography is a less specific diagnostic test
than biopsy11.
Some investigators have noted that PCNSV is hetero-
geneous in severity and therapeutic requirements3,7,12.
However, because of the lack of uniform diagnostic criteria
in various studies and the relatively small number of cases
reported, uncertainties exist about the clinical spectrum of
PCNSV, the factors that inf luence its response to treatment,
and its long-term outcome.
We recently identified 101 patients with PCNSV seen
at Mayo Clinic Rochester over a 21-year period17. Eight of
the 101 patients had a normal conventional angiogram but
had a brain biopsy result that was positive for vasculitis. We
describe the clinical characteristics of this subset of 8
patients and compare them with the characteristics of 76
other patients with PCNSV who had positive angiograms.
METHODS
Using the Mayo Clinic medical records linkage system
and chart reviews, we identified 101 patients with PCNSV
who were seen between January 1, 1983, and December 31,
2003. Patients were considered to have definite PCNSV if a
recent neurologic deficit occurred that was not explained by
other causes and if biopsy of brain or spinal cord showed
vasculitis, or if an angiogram showed changes highly sug-
gestive of vasculitis (that is, segmental narrowing, dilata-
tion, or occlusion affecting multiple cerebral arteries in the
absence of proximal vessel changes of atherosclerosis)17.
We excluded patients who had vasculitis outside the central
nervous system (CNS) and those with evidence of another
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disease that might explain the findings, such as systemic
lupus erythematosus or an underlying infection.
A standard data collection form was completed for all
101 cases. It included comprehensive information about
clinical findings at presentation and during follow-up,
laboratory investigations, results of CNS biopsy or autopsy,
response to treatment, follow-up functional status, and cause
of death. To assess treatment, we used the treating
physician_s global opinion about the patient_s response to
therapy.
The modified Rankin Scale was used to evaluate func-
tional status at presentation and at the latest visit19. A
standardized and commonly used scale, it measures dis-
ability or dependence in activities of daily living in stroke
victims. The scale consists of 7 scores: 0 corresponds to no
signs or symptoms; 1, no significant disability, despite symp-
toms; 2, slight disability; 3, moderate disability; 4, moder-
ately severe disability; 5, severe disability; and 6, stroke
death.
Vasculitis was found in 31 (63%) of 49 CNS tissue
specimens taken for diagnosis. A granulomatous inflamma-
tory histologic pattern was found in 18 patients (accompanied
by vascular deposits of amyloid " peptide in 8), a lympho-
cytic pattern in 8, and an acute necrotizing pattern in 5.
Changes of vasculitis were found in 76 (90%) of 84
angiograms. Angiograms alone were used to confirm the
diagnosis in 70 patients but were also positive in 6 additional
patients whose brain biopsy showed vasculitis. Eight patients
were observed whose angiograms were negative but who
had positive findings on brain biopsy, suggesting involve-
ment of small cerebral vessels that were below the resolution
of conventional angiography. We compared clinical and
laboratory findings in these 8 patients with those of the 76
patients who had angiography results that were positive for
vasculitis (Bangiography-positive[).
Statistical Analysis
Differences between the patients with small ves-
sel disease and those with angiography-positive PCNSV
were tested with 2-sided Wilcoxon rank sum tests for nu-
meric characteristics and Fisher exact tests for categorical
characteristics.
RESULTS
Demographic and Clinical Features
The demographic characteristics and clinical symptoms
of the 8 patients who had PCNSV with negative angiography
results (Bangiography-negative[) are compared in Table 1
with those of the other 76 patients in the cohort who had
angiography-positive PCNSV and are summarized individ-
ually in Table 2. Of the 8 patients, 4 were men. The median
age at diagnosis was 55.5 years (range, 26Y75 yr). The time
from onset of symptoms to diagnosis was less than 1 month
in only 1 of the 8 patients (median, 76 d; range, 17Y342 d).
Focal neurologic manifestations, headache, and presence of
a cognitive disorder were the most common symptoms at
presentation. One patient had mild left hemiparesis and 2
transient ischemic attacks. No focal cerebral manifestations
occurred later in the disease course of this patient. Four
patients had a rapid and dramatic cognitive decline: 1 patient
had a sudden change in level of consciousness; in the other








Male:female ratio 4:4 (50:50) 29:47 (38.2:61.8) .706
Age at diagnosis, yr 55.5 (26.0Y75.0) 46.0 (17.0Y81.0) .697
Period from symptom onset to diagnosis, d 76.0 (17.0Y342.0) 39.0 (2.0Y1913.0) .184
Headache 5 (62.5) 52 (68.4) .708
Cognitive disorder 7 (87.5) 33 (43.4) .024
Focal manifestations 8 (100) 75 (98.7) 1.000
Intracerebral hemorrhage 0 (0) 6 (7.9) 1.000
Systemic manifestationsy 3 (37.5) 9 (11.8) .083
CSF abnormality
Protein Q450 mg/L or WBC Q5  106/L 7 (100)z 35 (46) .096
Protein Q700 mg/L or WBC Q10  106/L 7 (100)z 27 (36) .034
ESR, mm/h 5.0 (1.0Y110.0) 10.0 (1.0Y107.0) .481
Modified Rankin Scale score at latest follow-up
0Y3 8 (100) 60 (78.9) .343
4Y6 0 (0) 16 (21.1)
Patients who were free of relapse or recurrence 4 (50.0) 58 (76.3) .197
Abbreviations: ESR = erythrocyte sedimentation rate, WBC = white blood cell.
*Categorical data are expressed as number and percentage of patients; continuous data are expressed as median and range.
yPresence of at least 1 of the following systemic manifestations: fatigue, anorexia, weight loss, fever.
zCSF findings recorded in 7 of the 8 patients.
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3 patients, the cognitive impairment was indolently prog-
ressive. Constitutional symptoms of anorexia with weight
loss, fatigue, or fever, or a combination, were present in 3
patients. Symptoms related to spinal cord involvement oc-
curred in 1 patient (Patient 3) at 19 months after symp-
tomatic brain involvement.








1 51/F Confusion, rapid cognitive decline, personality
change, mild left hemiparesis, aphasia
Multiple infarcts in central gray matter of both
cerebral hemispheres, involving
predominantly the heads of the caudate, as
well as portions of the lentiform, nucleus on
the left; extensive punctate and confluent
areas of increased T2 signal intensity in the
periventricular and subcortical white matter
tracts of both cerebral hemispheres; no
white matter lesion enhancement noted
2 mo
2 75/M Subacute dementia, personality change,
focal TIAs, aphasia
Small subcortical infarcts; several foci of
nodular enhancement in the sulci or adjacent
cortex; sulcal effacement most prominent in
the left frontal lobe associated with T2
hyperintensity in the sulci of the left frontal,
bilateral posterior temporal, bilateral
parietal, and bilateral occipital regions on
FLAIR images; subtle T1 hyperintensity in
left frontal lobe in the sulci or adjacent
cortex on T1-weighted sagittal images;
generalized prominence of vessels within
these abnormal sulci in both hemispheres on
T1-weighted images after contrast medium
2 mo
3 30/M Headache, confusion Gadolinium-enhancing mass in the deep white
matter of the right posterior frontoparietal
region
2 mo
4 31/F Sudden drowsiness at onset, confusion,
cognitive decline, personality change
(behavior like a baby), fatigue, headache,
aphasia
Diffuse decreased attenuation and increased
T2 signal in the white matter of both
cerebral hemispheres and confluent T2
signal abnormality extending from
subcortical to subependymal white matter;
diffuse small nodular foci of contrast
enhancement arranged in beadlike radial
strands from subependymal to subcortical
regions; changes more marked in frontal and
parietal lobes
5 mo
5 63/F Confusion, cognitive decline, headache, aphasia,
visual field defect
Diffuse leptomeningeal enhancement over left
cerebral hemisphere and right frontal and
temporal regions
17 d
6 26/M Ataxia, diplopia, nystagmus, fever (37.7 -C),
vertigo, dizziness, nausea, vomiting
Increased T2 signal in left midline cerebellar
area and brainstem; no abnormal meningeal
or parenchymal enhancement
11.5 mo
7 62/F Confusion, focal TIAs, headache, fatigue,
anorexia, weight loss
Area of abnormal T2 signal in anterior right
centrum semiovale and extending inferiorly
to involve the right basal ganglia; linear
areas of enhancement that converge adjacent
to body of right lateral ventricle in T2
abnormality
8 mo
8 64/M Confusion, rapid cognitive decline, personality
change, headache, ataxia
Diffuse leptomeningeal enhancement
involving both cerebral hemispheres and
cerebellum; multiple infarcts, patchy T2
abnormality of white matter
1.5 mo
Abbreviations: FLAIR = fluid-attenuated inversion recovery, TIA = transient ischemic attack.
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Other medical disorders were noted in 3 patients,
including hypothyroidism (2 patients) and Graves ophthal-
mopathy (1 patient).
Laboratory Investigations
Laboratory and pathology results at diagnosis are
shown in Tables 1 and 3. The erythrocyte sedimentation rate
was normal in 7 of the 8 patients (median, 5 mm/h; range,
1Y110 mm/h), and cerebrospinal fluid (CSF) examination
findings were abnormal in all 7 patients who had a spinal
tap. All 7 had a CSF protein level that was elevated above
700 mg/L (median, 1180 mg/L; range, 720Y5730 mg/L). Of
these 7 patients, 6 had an elevated CSF white blood cell
count of 10  106/L or more (median, 20  106/L; range,
2Y405  106/L). Lymphocytes were prevalent.
Radiology Results
As noted, results of conventional cerebral angiography
were negative in all 8 patients. Brain magnetic resonance
angiography was performed in 4 patients and showed no
evidence of vasculitis.
Brain magnetic resonance imaging (MRI) at presenta-
tion with and without contrast medium was abnormal in all 8
patients (Tables 2 and 4). Patchy or conf luent T2 abnormal-
ities were present in the T2-weighted images of 6 patients.
Enhancing lesions were observed in 6 patients: 2 patients
had prominent and diffuse leptomeningeal enhancement, 3
patients had multiple punctate or linear parenchymal
enhancing lesions, or both, and 1 patient had evidence of
an enhancing mass in the deep white matter. Evidence of
multiple infarcts was observed in 3 patients. No patients had
intracerebral hemorrhage.
Biopsy Results
Five open and 3 stereotactic brain biopsies were per-
formed (see Table 3), and all showed evidence of vasculitis.
In 5 patients, inf lammatory infiltration showed a granulo-
matous pattern (Figure 1); in 2 patients, a lymphocytic pat-
tern; and in 1 patient, a necrotizing pattern.
The inf lammation was mainly angiocentric in 7
patients and was also perivascular and parenchymal in 1
patient. In 3 patients, leptomeningeal and parenchymal
vessel involvement was observed; in 2, only leptomeningeal
vessels were involved; and in 3, only parenchymal vessels
were involved. In 3 patients, vascular deposits of amyloid,
with deposition of amyloid " peptide, were present.
Evidence of ischemic changes or infarcts was present in 3
patients.
Treatment and Outcome
The details of treatment, follow-up MRI, and the sta-
tus of patients at their last visit are shown in Table 5. The
median duration of follow-up was 19.5 months (range,
7Y105 mo). All patients were treated with prednisone. The
median starting dosage of oral prednisone therapy was
60 mg/d (range, 30Y80 mg/d). In 2 patients (Patients 2, 4),
oral prednisone treatment was preceded by methylpredniso-
lone pulse therapy (1 g/d intravenously for 3 d in Patient 2
TABLE 3. Laboratory and Pathology Results in 8 Patients With Small Vessel PCNSV
Patient
CSF
PathologyWBC (cells  106/L)
Protein
(mg/L) ESR (mm/h)
1 12 (92% lymphocytes,
8% monocytes)
720 110 Stereotactic brain biopsy: granulomatous leptomeningeal,
angiocentric inflammation
2 20 (95% lymphocytes,
5% monocytes)
1180 17 Open brain biopsy: granulomatous leptomeningeal, marked
angiocentric inflammation; " amyloid deposits
3 NA NA 2 Stereotactic brain biopsy: necrotizing intraparenchymal, marked
angiocentric inflammation associated with multiple acute/
subacute infarcts
4 14 (73% lymphocytes,
15% neutrophils, 12%
monocytes)
1290 5 Open brain biopsy: granulomatous intraparenchymal, marked
angiocentric inflammation
5 68 (78% lymphocytes,
17% monocytes, 5%
neutrophils)
5730 25 Open brain biopsy: granulomatous leptomeningeal and
intraparenchymal, marked angiocentric inflammation; "
amyloid deposits
6 2 (65% lymphocytes,
19% monocytes, 16%
neutrophils)
830 1 Stereotactic brain biopsy: lymphocytic intraparenchymal, marked
angiocentric inflammation; presence of infarcts
7 405 (95% lymphocytes,
5% monocytes)
1990 9 Open brain biopsy: lymphocytic leptomeningeal and
intraparenchymal, perivascular and parenchymal
inflammation
8 23 (90% lymphocytes,
10% monocytes)
970 2 Open brain biopsy: granulomatous leptomeningeal and
intraparenchymal, marked angiocentric inflammation; "
amyloid deposits; presence of infarct
Abbreviation: NA = not available.
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Prednisone alone 6 (75) 33 (44) .143y
Prednisone and cyclophosphamide (oral/pulse) 2 (25) 37 (49)
Prednisone and azathioprine 0 (0) 3 (4)
Cyclophosphamide oral alone 0 (0) 2 (3)
None 0 (0) 1 (1)
Duration of therapy, mo
Prednisone 12.5 (2.0Y100) 10.0 (1.0Y44.0) .558
Cyclophosphamide 6.0 (3.0Y91.0) 10.0 (1.0Y25.0) .623
Patients not taking therapy at latest follow-up 0 (0) 23 (31)z .099
Brain biopsy pattern
Lymphocytic 2 (25) 1 (20) 1.000
Granulomatous 5 (63) 4 (80)
Necrotizing only 1 (13) 0 (0)
CNS specimens with amyloid angiopathy 3 (38) 3 (13)‘ .161
MRI findings
Minimal/age-consistent white matter changes 0 (0) 2 (3)P 1.000
Presence of infarct 3 (38) 42 (63)P .254
Intracerebral hemorrhage 0 (0) 5 (8)P 1.000
Gadolinium-enhancing lesions (intracerebral
or meningeal)
6 (75) 16 (24)P .007
Gadolinium-enhancing lesions (intracerebral) 4 (50) 14 (21)P .088
Gadolinium-enhancing lesions (meningeal) 2 (25) 3 (5)P .085
*Categorical data are expressed as number and percentage of patients; continuous data are expressed as median and range.
yComparison of patients receiving therapy with any immunosuppressive agent and patients receiving therapy with prednisone alone.
zA total of 75 patients were considered because 1 patient had no therapy.
‘CNS specimens were available for 23 patients.
PA subset of 67 patients underwent MRI.
FIGURE 1. Photomicrograph of brain specimen including cortex and leptomeninges. Left, Small vessel with granulomatous
vasculitis (hematoxylin-eosin; original magnification  100). Normal small muscular artery is to right of involved vessel. Right,
Granulomatous character of inflamed vessel, with vessel wall destruction (hematoxylin-eosin; original magnification  400).
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and for 5 d in Patient 4); in 1 patient (Patient 3), it was prece-
ded by dexamethasone pulse therapy (24 mg/d intravenously
for 7 d). Additionally, 2 other patients (Patients 3, 6) received
methylprednisolone pulse therapy (1 g/d intravenously for 4 d)
for a relapse. The median duration of oral prednisone therapy
was 12.5 months (range, 2Y100 mo).
Initial treatment in 6 patients (Patients 2, 3, 4, 5, 6, 7)
was corticosteroid therapy alone. In 2 patients (Patients 1,
8), initial treatment was prednisone plus cyclophosphamide
therapy. Three patients (Patients 3, 4, 6) were treated with
prednisone and cyclophosphamide for a relapse. In the
overall disease course, 2 patients (Patients 6, 8) received
monthly pulse intravenous injections of cyclophosphamide,
2 patients (Patients 1, 4) received daily oral cyclophospha-
mide, and 1 patient (Patient 3) received both monthly
intravenous cyclophosphamide pulse therapy and daily oral
cyclophosphamide at different times during the disease
course. The median duration of cyclophosphamide treatment
was 6 months (range, 3Y91 mo).
Of the 8 patients, 4 (Patients 3, 4, 5, 6) had a relapse.
Patient 3 was initially treated with dexamethasone pulse
therapy, oral prednisone, and monthly pulse intravenous
cyclophosphamide injections for neurologic symptoms
related to vasculitic involvement of the brain. His condition
dramatically improved, and 3 months later, his neurologic
examination was normal. However, 13 months laterVwhile
he was taking prednisone (5 mg/d)Vhe had a relapse
involving the spinal cord. The patient was treated with
methylprednisolone pulse therapy, oral prednisone, and oral
cyclophosphamide and had partial improvement in his
neurologic status during the 1-month follow-up period.
Patient 4 had a relapse as her oral prednisone dosage
was being reduced after 4 months of treatment. Oral
cyclophosphamide was added to the prednisone. However,
TABLE 5. Treatment, Outcome, and Follow-Up Duration in 8 Patients With Angiography-Negative PCNSV







1 Prednisone (initial dosage, 50 mg/d)  6 mo
and oral cyclophosphamide (100 mg/d) 
6 mo
Cystic degeneration of some older infarcts;
extensive increased T2 signal was
unchanged in the region of the centrum
semiovale and subcortical white matter
throughout entire cerebrum
Improved 1 8
2 Methylprednisolone (1 g/d IV)  3 d, then
oral prednisone (initial dosage, 60 mg/d) 
4 mo
NA Stable 3 7
3 Dexamethasone (24 mg/d IV)  7 d, then
oral prednisone (60 mg/d, reduced to
5 mg/d)  16 mo and cyclophosphamide
(1 g/mo IV)  5 mo
NA Improved 1 19
Treatment of relapse:
Methylprednisolone (1 g/d IV)  4 d, then
oral prednisone (60 mg/d) and oral
cyclophosphamide (125 mg/d)  1 mo
4 Methylprednisolone (1 g/d IV)  5 d, then
oral prednisone (initial dosage, 60 mg/d) 
100 mo and cyclophosphamide (initial
dosage, 150 mg/d)  91 mo
Resolution of extensive punctuate foci of
contrast enhancement, no significant
changes in the conf luent area of increased
T2 signal in the white matter of both
hemispheres
Improved 2 105
5 Prednisone (initial dosage, 80 mg/d) 
13 mo
Resolution of leptomeningeal enhancement Improved 1 87
6 Prednisone (initial dosage, 40 mg/d) 
15 mo, cyclophosphamide (500 mg/mo IV)
 3 mo, and methylprednisolone
(1 g/d IV)  4 d
NA Stable 2 26
7 Prednisone (initial dosage, 60 mg/d) 
12 mo
Resolution of enhancing lesions Improved 0 20
8 Prednisone (initial dosage, 30 mg/d)  2 mo,
cyclophosphamide (1.7 g/mo IV)  14 mo
Resolution of leptomeningeal enhancement;
absence of new, recent infarcts
Improved 1 15
Abbreviations: IV = intravenous, MRS = modified Rankin Scale score.
*0, no symptoms; 1, no significant disability, despite symptoms; 2, slight disability; 3, moderate disability; 4, moderately severe disability; 5, severe
disability; 6, stroke death.
yFrom the onset of symptoms.
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she was unable to decrease her prednisone dosage to less
than 20 mg/d because of a relapsing course of the disease
(4 other relapses) during the 9-year follow-up period. In all
the relapses, an increased dosage of oral prednisone resulted
in rapid improvement of neurologic status.
Patient 5, initially treated with prednisone, had a re-
currence characterized by headache, confusion, and expres-
sive aphasia 6 years after suspension of therapy. At the
recurrence, results of brain MRI showed the reappearance of
meningeal enhancement. She was treated again with pred-
nisone alone and had complete remission on the basis of
neurologic and MRI findings.
Patient 6 initially received prednisone and monthly
pulse intravenous injections of cyclophosphamide. The
cyclophosphamide therapy was stopped after the third
injection because of improvement in his neurologic status.
Nine months later, however, he had a relapse characterized
by the reappearance of diplopia, dizziness, nausea, and
vomiting. Pulse glucocorticoid therapy (1 g/d of methyl-
prednisolone) was given for 4 days, after which the oral
prednisone dosage was increased to 60 mg/d. His neurologic
status improved dramatically within days.
In summary, all 8 patients responded well to therapy.
Response was rapid and generally noted in the first 2Y3
weeks of treatment. A rapid response was also noted in the 4
patients who had relapses. Follow-up MRI studies were
available in 5 patients, and gadolinium enhancement was no
longer detectable after therapy. In 2 patients, the extensive
areas detected on T2-weighted imaging did not change.
Outcome was favorable in all patients. No patients had
permanent major neurologic dysfunction. Five patients had
total or nearly total recovery, and 3 patients had recovery
with residual disability that was slight or moderate. The
median modified Rankin Scale score at the latest visit was 1
(range, 0Y3), compared with the median value of 2 (range,
1Y4) at presentation. No deaths occurred.
Comparison of Angiography-Negative and
Angiography-Positive PCNSV
The 8 cases of angiography-negative PCNSV are com-
pared with the 76 cases of angiography-positive PCNSV in
Tables 1 and 4. The comparison showed that the presence of
a cognitive disorder (87.5% vs. 43.4%; p = .024), CSF
abnormalities (a protein level Q700 mg/L or a white blood
cell count Q10  106/L) (100% vs. 35.5%; p = .034), and
gadolinium-enhancing lesions (75.0% vs. 23.9%; p = .007)
were significantly more frequent in patients with angiog-
raphy-negative PCNSV than in the others. Parenchymal and
meningeal gadolinium-enhancing lesions were also more
frequently seen in the patients with angiography-negative
PCNSV. Prominent leptomeningeal enhancement and paren-
chymal multiple punctate areas of gadolinium enhancement
were observed only in patients with small vessel PCNSV.
Patients with angiography-negative PCNSV had a
greater median age at diagnosis. They had a less acute
clinical onset and a higher median period from onset of
symptoms to diagnosis, and they more frequently had
constitutional symptoms at diagnosis. However, these differ-
ences were not significant. In addition, they were more often
treated initially with glucocorticoid therapy alone and less
often in combination with cyclophosphamide.
Although none of the 8 with angiography-negative
PCNSV had severe disability or died during follow-up,
relapses were common, and all of them were receiving
therapy at latest follow-up.
DISCUSSION
In our analysis of 101 patients with PCNSV who were
seen at our institution over 21 years17, we noted that 8
patients whose brain biopsy findings showed vasculitis had
normal angiograms. We assume that these 8 had involve-
ment only of small cerebral vessels that were below the
resolution of conventional angiography. To determine
whether the 8 patients had clinical characteristics different
from those of other patients with PCNSV, we compared
them with 76 patients who had angiography-positive
PCNSVVthat is, the patients with inf lammation in vessels
that were large enough to be visualized on angiography.
Although the findings in the 8 patients were not identical,
there were sufficient similarities among these 8 cases to
suggest that they represent a recognizable subgroup in the
spectrum of PCNSV.
The prominent clinical feature of the 8 cases with
small vessel PCNSV was the presence of cognitive dysfunc-
tion that was significantly more frequent in these patients
than in the 76 patients with angiography-positive PCNSV. In
most of the 8 cases, the cognitive impairment was rapid and
dramatic.
Although the 8 patients with angiography-negative
PCNSV had a higher frequency of systemic manifestations,
erythrocyte sedimentation rates were normal in 7 patients
and were not useful in differentiating them from the other 76
patients. CSF abnormalities were significantly more marked
in patients with angiography-negative PCNSV. In particular,
they presented a striking elevation in median total protein
level (median, 1180 mg/dL; range, 720Y5730 mg/dL), which
was also higher than the median value reported in our total
cohort of 101 patients (median, 72 mg/dL; range,
15Y1034 mg/dL)17. This marked elevation in total protein
level may reflect a more diffuse nature in the intracranial
inf lammatory processes and provides evidence that these
patients may represent a relatively homogeneous disease
subset.
MRI results were abnormal in all patients with
angiography-negative PCNSV5,10. Meningeal and parenchy-
mal enhancement was observed significantly more often in
the 8 patients with angiography-negative disease than in
those with angiography-positive PCNSV. Leptomeningeal
enhancement was present in 2 of the 8 and has been
previously described in several reports8,9,14,16.
Gadolinium enhancement of parenchymal multiple
punctate areas or linear areas, or both, represents a different
pattern of enhancement that was observed in 3 of our
patients (Patients 2, 4, 7). To our knowledge, this pattern has
been previously reported in only 1 patient with histologic
evidence of PCNSV in whom, as in our cases, angiography
results were negative for vasculitis18. This pattern of
enhancement is probably due to a combination of vascular
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and perivascular inflammatory changes that include the
meninges and surrounding gray and white matter. Some
investigators have suggested that this Bperivascular[ type of
enhancement, although unusual, could be specific to
PCNSV5. In the current study, Patient 3 had evidence of a
gadolinium-enhancing mass in the deep white matter. The
brain biopsy performed to evaluate for a neoplastic condition
unexpectedly revealed PCNSV. Duna et al6, in their review
of published analyses, observed that in 15% of the reported
PCNSV cases, patients had a mass lesion at presentation.
Such gadolinium-enhancing lesions on MRI are not specific
for vasculitis.
Although the clinical findings in the 8 patients with
angiography-negative PCNSV were similar, the histologic
pattern found on brain biopsy was not uniform. Granuloma-
tous inf lammatory pattern was prevalent and seen in 5 of the
8 patients; however, lymphocytic and acute necrotizing
patterns were also observed. In 5 patients, biopsy samples
showed evidence of vasculitis in leptomeningeal vessels (in
2 patients, only leptomeningeal vessels were involved). An
optimal biopsy should include adequate samples of dura,
leptomeninges, cortex, and white matter15.
The published findings on the therapy response and
outcome of PCNSV are varied. Earlier reports considered
PCNSV a progressive CNS disorder that had a fatal course
unless it was treated vigorously with glucocorticoids and
immunosuppressive agents2,4,13. More recent case reports
have indicated subsets of patients with different prognoses
and treatment requirements3,7,12. In our cohort of 101 patients
with PCNSV, we found a favorable response to glucocorti-
coids both alone and in conjunction with cyclophosphamide
in most patients17.
Patients with angiography-negative PCNSV appeared
to have a more relapsing, benign disease than patients who
had angiography-positive PCNSV. Although they had more
relapses, they were less frequently treated initially with
immunosuppressive agents. MacLaren and colleagues12 also
noted more frequent relapses in patients they designated as
having small vessel disease. However, of the 12 patients
they studied, only 1 of the 6 cases of small vessel PCNSV
had brain biopsy results that confirmed the diagnosis.
In 2005, Benseler and coworkers1 reported on 4 children
with angiography-negative, biopsy-confirmed small vessel
PCNSV that they considered a new disease entity belonging
to the spectrum of childhood PCNSV. Neurocognitive
dysfunction was the most frequent neurologic deficit at
diagnosis, CSF abnormalities were present in all patients,
and immunosuppressive therapy led to an excellent neuro-
logic outcome. A lymphocytic vasculitis of the small arterial
vessels was the histologic finding observed on brain biopsy in
the 4 children. Although the histologic pattern was different
from the one we observed, the pediatric and our adult forms
of angiography-negative PCNSV had similar clinical findings.
The identification of 8 patients with angiography-
negative PCNSV in our consecutive series of 101 cases
diagnosed by predefined criteria provides an estimate of the
relative frequency of this subset. However, the retrospective
nature of our larger series with the potential for referral bias
is a limitation.
In conclusion, we describe a group of patients with
PCNSV whose angiograms were normal but findings on
brain biopsy were positive. These findings suggest that the
vasculitis was limited to small vessels beyond the resolution
of conventional angiography. These patients had the follow-
ing characteristics more frequently than patients with
angiography-positive PCNSV: 1) cognitive dysfunction at
presentation; 2) greater CSF abnormalities, in particular a
marked elevation in total protein level; and 3) meningeal or
parenchymal enhancing lesions present at MRI.
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